|
|
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
The
|
||
|
|
The
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
15,701,264
|
1,228,898
|
43,118
|
N/A
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
13,948,381
|
189,458
|
12,175
|
2,823,265
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
16,263,251
|
618,234
|
91,794
|
N/A
|
CYCLO THERAPEUTICS, INC.
|
||
Date: December 26, 2023
|
By:
|
/s/ N. Scott Fine
|
N. Scott Fine, Chief Executive Officer
|
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end
X!=Q'PJ3+&5\X6 34HOX4A]^%RE_.-2CU?KIM/2@4_+B;U1KY2?7.Z5X!8
M>;-6?<,CQL/*UZTRA.X9D+R64"2Y29+8>WT+09Y+"/*V0W)_MNU59XO?=DA>
M91CRJI%_DJ');FA?&\ \KM>Y#RX6N%G5M]!DB)5DJLUM6DGQP4!)3.LU*D+\<%*0T=6>ERI6#JI0D"NT<-$?\57.6
MTDX&1QS5\O2HG12.>*L6*5D[/1QQ5ZLRP79B..*>VB:>[41QQ%,]+<-M)XTC
MWFIY:MU."D>\U)*TOIT.CCBGU>\2V,GAE%=J\>:"7<3,$;>TY*T).QT<\4LM
MWM0XR#B$1Y) QX^?]C7JC_IO&"CY'U!+ P04 " #J@9I7A<(=H542 "=
MC0 $P &-T9&@R,#(S,3(R-E\X:RYH=&WM76MSVDB7_CRIVO_0R[PSKU.%
M DP%SM4$6(GKL38!>2=V?TRU4@-]$1(3+=DP_[Z/:=; @D+@QW?[9G)$-'W
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M;*9KQ T Y#4DLVD0+\(R4W(29,I)5